Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORIN1001 + paclitaxel protein-bound
- Development stage
- Unknown
- Lead developer
- Orinove
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of ORIN1001 and paclitaxel protein-bound (nab-paclitaxel). Paclitaxel protein-bound is a formulation where paclitaxel particles are bound to albumin protein. It works by disrupting the microtubular network essential for cell division, preventing the normal breakdown of microtubules during cell division, eventually causing cancer cell death.
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ORIN1001 + paclitaxel protein-bound.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORIN1001 + paclitaxel protein-bound.